<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1762">
  <stage>Registered</stage>
  <submitdate>20/11/2007</submitdate>
  <approvaldate>20/11/2007</approvaldate>
  <nctid>NCT00562497</nctid>
  <trial_identification>
    <studytitle>Efficacy and Safety of Prochymal Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD</studytitle>
    <scientifictitle>A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>265</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Graft Versus Host Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Prochymal
Other interventions - Placebo

Placebo Comparator: 2 - Placebo

Active Comparator: 1 - Subjects assigned to the active treatment group will receive Prochymal.


Treatment: drugs: Prochymal
Subjects will be treated with a total of 6 infusions of investigational agent during the first 4 weeks of the study. Four infusions will be administered during the first two weeks (twice weekly), then two infusions administered during the next two weeks (once weekly). Subjects assigned to the active treatment group will receive Prochymal at 2 x 106 hMSC/kg per infusion.

Other interventions: Placebo
Subjects will be treated with a total of 6 infusions of investigational agent during the first 4 weeks of the study. Four infusions will be administered during the first two weeks (twice weekly), then two infusions administered during the next two weeks (once weekly). Subjects assigned to the non active treatment group will receive placebo (excipient, less cells). It is recommended that all subjects receive all six infusions. The discontinuation of investigational agent is allowed for GVHD worsening with subsequent need for salvage therapy. All infusions must be given at least 3 days apart.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Achieved an induction of a complete response, Followed by 28 days of maintenance of a clinically meaningful response that does not did not require an increase in corticosteroid dose , did not require second line therapy and survived 90 days.</outcome>
      <timepoint>90 Days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response, Induction of a two grade decrease in GVHD and Maintenance, Induction of a CR lasting =14 days, Time to CR, Incidence of CR per organ, Total steroid dose through Day 90, Incidence of Steroid/Infectious complications</outcome>
      <timepoint>90 Days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects must be 18 years to 70 years of age, inclusive

          -  Subjects must have received an allogeneic hematopoietic stem cell transplant using
             either bone marrow, peripheral blood stem cells or cord blood or administered a donor
             leukocyte infusion.

          -  Subjects must have newly diagnosed Grades B-D acute GVHD. Biopsy confirmation of GVHD
             is strongly recommended but not required. Randomization should not be delayed awaiting
             biopsy or pathology results.

          -  Subjects must be randomized and treated with corticosteroid (1-2 mg/kg/d
             methylprednisolone, or equivalent) and Prochymal/placebo within 72 hours of onset of
             acute GVHD.

          -  Subjects must have adequate renal function as defined by: Calculated Creatinine
             Clearance of &gt;30mL/min using the Cockroft-Gault equation

          -  Subjects who are women of childbearing potential, must be non-pregnant, not
             breast-feeding, and use adequate contraception. Male subjects must use adequate
             contraception

          -  Subject must have a minimum Karnofsky Performance Level of at least 30 at the time of
             study entry

          -  Subject (or legal representative where appropriate) must be capable of providing
             written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject has been previously treated with systemic immunosuppressive therapy for acute
             GVHD

          -  Subject has any underlying or current medical or psychiatric condition that, in the
             opinion of the Investigator, would interfere with the evaluation of the subject
             including uncontrolled infection, heart failure, pulmonary hypertension, etc.

          -  Subjects may not receive any other investigational agents (not approved by the FDA for
             any indication) concurrently during study participation or within 30 days of
             randomization.

          -  Subject has a known allergy to bovine or porcine products or DMSO

          -  Subject has received a transplant for a solid tumor disease.

          -  Subject requires more than 2L/min of oxygen to maintain stable SaO2 greater than or
             equal to 92%

          -  Subject requires a renal dopamine dose greater than 1-3 mcg/kg/min to maintain renal
             blood flow associated with renal failure and improved urinary output.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>184</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2010</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <hospital>St. Vincent's Hospital - Darlinghurst</hospital>
    <hospital>Royal Brisbane Hospital - Herston</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6001 - Perth</postcode>
    <postcode>NSW 2010 - Darlinghurst</postcode>
    <postcode>QLD 4029 - Herston</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Mesoblast International SÃ rl</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase III, randomized, double-blind, placebo-controlled study to investigate the
      efficacy and safety of Prochymal versus placebo in combination with corticosteroids as
      initial therapy for acute GVHD. Corticosteroids have been the primary therapy for patients
      with previously untreated acute GVHD and the historical published data define an expected 35%
      complete response (CR) at Day +28 using this therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00562497</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Rod L Monroy, Ph.D.</name>
      <address>Osiris Therapeutics, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>